What is Gradient Denervation Technologies?
Gradient Denervation Technologies is a Paris-based medical device company dedicated to developing a minimally invasive, ultrasound-based system for treating pulmonary hypertension, particularly in patients with left-sided heart disease. Their proprietary Gradient Denervation System employs therapeutic ultrasound energy to target and ablate nerves surrounding the pulmonary artery. This addresses a critical unmet need in a patient demographic with limited therapeutic options. The company's technology is rooted in intellectual property originating from Stanford University, with the ambition to fundamentally alter the treatment paradigm for pulmonary hypertension. Their primary clientele includes healthcare providers and patients affected by this condition.
How much funding has Gradient Denervation Technologies raised?
Gradient Denervation Technologies has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2023): $15M with participation from Sofinnova Partners, Asabys Partners, and Thuja Capital
Key Investors in Gradient Denervation Technologies
Sofinnova Partners
Sofinnova Partners is a prominent European venture capital firm with a deep specialization in life sciences, focusing on healthcare and sustainability. They are known for their hands-on approach, acting as company builders across the entire life sciences investment spectrum, from seed to later stages.
Asabys Partners
Asabys Partners is an investment firm based in Barcelona that concentrates on advancing breakthrough innovations within the healthcare and life sciences sectors. They invest in highly innovative technologies aimed at improving patient outcomes and collaborate closely with portfolio companies to provide expert support.
Thuja Capital
Thuja Capital is a leading early-stage venture capital firm in Europe, dedicated to investing in innovative life science companies. They partner with visionary leaders to drive transformative healthcare solutions by leveraging extensive sector expertise and a robust network.
What's next for Gradient Denervation Technologies?
The substantial enterprise-level capital infusion, highlighted by the recent strategic investment, positions Gradient Denervation Technologies for significant growth and market penetration. This financing is anticipated to fuel further research and development, expand clinical trial initiatives, and scale manufacturing capabilities. The company's focus on a complex cardiovascular condition with limited effective treatments suggests a strong market opportunity. Future strategic moves will likely involve navigating regulatory pathways, forging key partnerships within the healthcare ecosystem, and preparing for broader market adoption of their innovative ultrasound-based denervation system.
See full Gradient Denervation Technologies company page
